A MINIMALLY INVASIVE HEMODYNAMIC MONITORING DEVICE FOR THE BRAZILIAN HEALTH SYSTEM- IS FLOTRAC® COST-EFFECTIVE?
Author(s)
Okumura LM1, Riveros BS2, Lucchetta RC2, Rosim MP3, Nita ME4, Goodall G5, Ferreira CN6
1Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Universidade de São Paulo, São Paulo, Brazil, 4Market Access and Patient Engagement Solutions - MAPES, São Paulo, Brazil, 5Edwards Lifesciences SA, Nyon, Switzerland, 6Edwards Lifesciences Latam, São Paulo, Brazil
OBJECTIVES:: To assess the cost-effectiveness of a minimally invasive method of hemodynamic monitoring for high risk surgical procedures for the Brazilian Health System METHODS:: A decision tree model was created to assess the efficiency of FloTrac® used to implement a goal-directed therapy (GDT) protocol in comparison to a conventional scenario without GDT. A systematic search was conducted in the main international database to find relevant clinical outcomes (e.g.: perioperative complications probabilities), whereas costs were derived from DATASUS and SIGTAP, two formal Brazilian database with costs and health-related information. To assess the uncertainty from the model, univariate and probabilistic sensitivity analyses were used and reported as tornado diagram and incremental cost-effectiveness scatterplot, respectively. RESULTS:: In the non-GDT group, the number of perioperative complications per patient was 0.87 and costed R$ 10,600; while in the FloTrac® group, the number of complications per patient was 0.3 and costed R$ 8,766. Therefore, by considering the complications avoided, FloTrac® appears as dominant over non-GDT in base case scenario. In one-way and probabilistic sensitivity analysis, FloTrac® remained the dominant arm, where it could be observed that critical variables did not alter the previous conclusions based on the ICER and remained at higher probabilities of incremental effectiveness and lower costs. CONCLUSIONS:: The hypothesis that the minimally invasive hemodynamic monitoring device, FloTrac®, was cost-effective for the Brazilian Health System was confirmed by the findings from this economic analysis.
Conference/Value in Health Info
2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PMD27
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders